Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Agenus ( (AGEN) ) has provided an update.
Agenus Inc. has secured a $22 million mortgage to bolster its cash reserves and support strategic operational realignment, focusing on its promising immunotherapy candidates, botensilimab and balstilimab, for colorectal cancer. The loan, facilitated by L&L Capital, involves a two-year term with interest payable in cash and stock. Agenus aims to significantly cut costs and transform its manufacturing operations while advancing its clinical programs, positioning itself for growth and innovation in cancer treatment.
Learn more about AGEN stock on TipRanks’ Stock Analysis page.
